Paul Hastings LLP advised Jasper Therapeutics, Inc. (Nasdaq: JSPR) in connection with the company’s underwritten offering of 3,900,000 shares of its common stock. Each share of common stock will be sold at an offering price of $12.95 per share, for gross proceeds of approximately $50 million, before deducting underwriting discounts and commissions and offering expenses. Jasper Therapeutics is a clinical-stage biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU) and lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes.

Partner and chair of the Corporate Practice in Palo Alto Jeff Hartlin and partner Samantha Eldredge led the Paul Hastings team, which also included associates Jenna Barba and Shawn Kim.

More details about the transaction can be found here.

About Paul Hastings

With widely recognized elite teams in finance, mergers & acquisitions, private equity, restructuring and special situations, litigation, employment, and real estate, Paul Hastings is a premier law firm providing intellectual capital and superior execution globally to the world’s leading investment banks, asset managers, and corporations.